Anti-Claudin-5 (C-terminal) antibody produced in rabbit, approx. 1.0 mg/mL, affinity isolated antibody

Not available outside of the UK & Ireland.

Application

Anti-Claudin-5 (C-terminal) antibody has been used in Iimmunoblottingimmunofluorescence immunohistochemistry immunolabellingimmunocytochemistry

Biochem/physiol Actions

Claudin-5 has been shown to be overexpressed in various tumors including lung adenocarcinomas but undetectable in squamous cells cell carcinomas.

Claudin-5 (CLDN5), as an essential component of blood-brain barrier (BBB), plays a vital role in regulating the homeostasis of the central nervous system. Mutation in the gene increases the risk of susceptibility to schizophrenia. Overexpression of the gene is associated with the progression of pancreatic ductal adenocarcinomas. Loss of CLDN5 in cardiomyocytes and endothelial cells is one of the main reason behind human heart failure. Hence, early usage of CLDN5 can be considered as a potential therapeutic target for heart failure.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Claudin-5 (CLDN5) is encoded by the gene mapped to human chromosome 22q11.21. The encoded protein a 23kDa, four-transmembrane protein. It is mainly expressed in endothelial cells forming part of the blood-brain barrier (BBB).

Immunogen

synthetic peptide corresponding to a sequence at the C-terminus of human claudin-5, conjugated to KLH. The corresponding sequence is highly conserved in mouse claudin-5 (single amino acid substitution) and in rat claudin-5 (89% identity).

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.